INTRODUCTION
Childhood obesity has become a global epidemic 1 and there is growing evidence that it starts very early in life, potentially during the perinatal period. 2, 3 To date, little is known on the potential role of the long-chain PUFA (LCPUFA) profile on body composition in the offspring, although this aspect has recently gained increasing attention. 4 According to a hypothesis introduced by Ailhaud et al. 5 reducing the n-6/n-3 fatty acid ratio in the maternal diet may help to limit early adipose tissue growth in the offspring and may thereby represent a novel strategy for the primary prevention of childhood obesity. Although it is feasible to enhance the n-3 LCPUFA profile of neonates by nutritional intervention 6 or dietary supplementation [7] [8] [9] [10] [11] [12] of their mothers during pregnancy, the effects of a concomitant modification of the dietary n-6 fatty acid intake on the n-6/n-3 fatty acid balance of the pregnant women as well as her neonate has not been investigated so far, despite the fact that the dietary intake of n-6 fatty acids has changed dramatically over the last decades. 5 We recently reported the key clinical results of the INFATstudy which is the first prospective randomized controlled trial to assess the combined effects of n-3 LCPUFA supplementation and concomitant reduction in n-6 arachidonic acid (AA) intake in pregnant/lactating women on growth and body fat mass in the offspring from birth up to the first year of life, assessed by skinfold thickness (SFT) investigations and abdominal ultrasonography. 13 We could not verify our initial hypothesis because no antiobesity effect of the specific dietary intervention was found in the intervention group. However, as it has been documented that pregnant women consuming n-3 fatty acids have a quite variable response to n-3 fatty acid supply, for example, due to the prior LCPUFA profile, mobilization from adipose tissue stores or specific genetic variations, 14 complementary analysis based on the individual n-6/n-3 LCPUFA ratio (irrespective of group allocation) is warranted to further clarify the role of LCPUFAs in perinatal growth and early human adipogenesis.
In this consecutive analysis, we took advantage of the broad spectrum of the n-6/n-3 fatty acid ratio achieved in the INFAT population and explored in detail the association between maternal LCPUFA concentrations during late pregnancy, cord blood LCPUFA concentrations and infant growth and body fat mass up to the first year of life.
MATERIALS AND METHODS

Study design, subjects and intervention
Details on the INFAT-study design, clinical outcomes and inclusion and exclusion criteria have been recently published elsewhere. 13, 15 Briefly, healthy pregnant women were recruited around the 14th week of gestation and randomly assigned either to a dietary intervention or a control group from the 15th week of gestation until 4 months postpartum (pp). The dietary intervention group received a fish oil supplement throughout pregnancy and lactation (Marinol-D40, Lipid Nutrition, Loders Crocklaan, the Netherlands) providing 1200 mg n-3 LCPUFA (1020 mg DHA and 180 mg eicosapentaenoic acid (EPA)) from fish oil in glyceride form and 9 mg vitamin E. Simultaneously, the women received a detailed dietary counseling to normalize their AA-intake to the recommended range of 50-100 mg per day. Participants of the control group received a brief semi-structured counseling on a healthy balanced diet according to the guidelines of the German Nutrition Society. 13, 15 The study protocol was in accordance with the rules of the International Conference on Harmonization Good Clinical Practice guidelines (ICH-GCP, valid from 1997/1/17), the last revision of the declaration of Helsinki (October 2000, Edinburgh, UK) and applicable local regulatory requirements and laws. The study protocol was approved by the ethical committee of the Technische Universität Mü nchen (No. 1479/06/2006/2/21).
Data and blood sample collection
Medical history and demographic information were collected at screening in the study center. Compliance was assessed by self-reported capsuleintake counting. Maternal fasting blood samples were collected at 15th week of gestation (baseline), at 32nd week of pregnancy and at 6 week and 4 months pp, if mothers were breastfeeding their infant. Cord blood was sampled from the umbilical vein at delivery. To monitor the compliance with the AA-balanced diet women completed a 7-day dietary record at the 32nd week of pregnancy. 13 Birth measures and sex of the newborns were extracted from the maternal obstetric record. At visit, 6 week, 4 and 12 months pp weight and height of the infant was measured in the study center and four-sided SFT measurements were performed under standardized conditions with a caliper (Holtain Ltd, Croswell, Crymych, UK) as described previously. 13 The calculation of body fat (%) was determined via predictive skinfold equations according to the method of Weststrate et al. 16 Abdominal ultrasonography was performed by two well-trained pediatricians, blinded to group allocation. Abdominal subcutaneous fat and preperitoneal fat thickness, the latter considered to be an approximation of visceral/ intraabdominal fat, 17 were measured longitudinally as areas of 1-cm length just below the xiphoid process at 6 week, 4 and 12 months pp. 13 Fatty acid analysis in plasma phospholipids (PLs) and red blood cells (RBCs) The analysis of fatty acids in PLs and RBCs was performed in the Laboratory of Lipid Research, Danone Research-Center for Specialised Nutrition, Friedrichsdorf, Germany according to established protocols. 18, 19, 20 All analyses were done in duplicate. Fatty acid values are presented in % FA/ total FA (% of total FAs).
Statistical analysis
Due to the exploratory nature of the statistical analyses performed here and due to the large number of investigated variables non-parametric tests were used in this analyses, which were more conservative and more economic, as there was no need for particular proof of assumptions regarding the underlying data distribution (for example, normality). 21 A two-sided P-valueo0.05 was considered statistically significant.
Differences in fatty acid values between the groups were compared using the Mann À Whitney-U-Test. Bonferroni correction of P-values was applied to reduce multiple test issue within multiple sample analysis. For this purpose, the P-value was divided by the factor four, due to the four time points investigated in this study. Changes in the maternal fatty acid profile over time were determined by using the Friedman-Test. To determine the relationship between fatty acid proportions in maternal/ fetal RBCs and infant outcomes, partial correlation coefficients were calculated based on the entire study cohort in addition to multiple linear regression models (F-test, analysis of covariance). As the main neonatal outcomes (birth weight, body mass index (BMI) (kg/m 2 ) and PI (kg/m 3 ) at birth) were strongly affected by pregnancy duration, 13 adjusted analysis was performed to correct for effects mediated by pregnancy duration and other relevant confounders (for example, group, parity, sex, PI at birth and breastfeeding status). Statistical analyses were performed using the software package R version 2 Á 8 Á 1 (R Foundation for Statistical Computing, Vienna, Austria) and PASW software (version 17 Á 0, SPSS Inc., Chicago, IL, USA). Maternal fatty acid profile over the course of pregnancy and lactation At study entry, there were no statistically significant differences in the fatty acid composition of RBCs (Table 1 ) and plasma PLs (data not shown) between the intervention and the control group.
RESULTS
Participant characteristics
Supplementation with fish oil and the concomitant AAbalanced diet starting from the 15th week of gestation onwards until 4 months pp resulted in a significant increase in the percentage of EPA, DHA and the sum of n-3 LCPUFA in maternal RBCs at 32nd week of pregnancy and at 6week and 4 months pp compared with the control group (Table 1) .
In contrast, the proportions of AA and n-6 LCPUFA in RBCs were significantly lower in the intervention group at 32nd week of pregnancy and throughout lactation compared with the control group, resulting in a remarkable, significant decrease of the AA/ DHA and the n-6/n-3 LCPUFA ratio in maternal RBCs at 32nd week of gestation, 6 week and 4 months pp compared with control participants. Similar changes were obtained by analyzing the fatty acid profile of maternal plasma PLs (data not shown).
Cord blood fatty acid profile Umbilical cord RBCs samples were available from 132 newborns (C/I ¼ 65/67). In umbilical RBCs the EPA, DHA and n-3 LCPUFA contents were significantly higher in the intervention group than in the control group (Table 2) .
Conversely, the AA/DHA ratio and the n-6/n-3 LCPUFA ratio as well as MUFA contents were significantly lower in the intervention group compared with the control group. Umbilical RBCs contents of AA were comparable between groups (Table 2) . Basically, the same picture was observed in the fatty acid profiles of plasma PLs (data not shown).
We also explored the impact of gender on the fatty acid profile. In a model with the respective fatty acid as dependent variable and group*sex interactions of the newborns as influencing factor, no significant interaction between sex and intervention was observed for the fatty acid values in umbilical cord blood (data not shown).
Relationship between maternal fatty acid profile at 32nd week of gestation and cord blood fatty acid profile Maternal plasma PLs AA, DHA, EPA, AA/DHA ratio, total n-3 LCPUFA, total n-6 LCPUFA and the n-6/n-3 LCPUFA ratio at 32nd wk of gestation were significantly positively correlated with the respective fatty acid levels and ratios in umbilical cord blood PLs (for example, n-6/n-3 LCPUFA ratio: r ¼ 0.80, Po0.01). Most correlations between maternal and cord blood fatty acids in RBCs were significant, except for AA and n-6 LCPUFA, but clearly less pronounced than in the PLs (data not shown).
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Maternal LCPUFA profile in relation to infant growth parameters and fat mass Maternal RBCs DHA, total n-3 LCPUFAs and total n-6 LCPUFAs at the 32nd week of gestation were significantly positively related with birth weight (Po0.05) in analyses corrected for relevant confounders (Table 3) . Total RBCs n-3 LCPUFAs, n-6 LCPUFAs and AA were significantly positively associated with length at birth (Po0.05, Table 3 ). RBCs n-3 LCPUFAs and n-6 LCPUFAs were significantly positively associated with head circumference at birth (Po0.05, Table 3 ).
The n-6/n-3 LCPUFAs ratio at 32nd week of gestation was significantly negatively related to length at birth ( À 0.36 (95%: confidence interval À 0.69, À 0.03); P ¼ 0.034).
Maternal RBCs EPA (data not shown), DHA, n-3 LCPUFAs, AA and n-6 LCPUFAs at 32nd week of gestation were significantly positively related with newborn lean body mass (g) at birth when corrected for gestational age, parity, sex and group (Table 4) . Maternal RBCs n-3 LCPUFAs were significantly positively related to fat mass (g) at birth in the adjusted analysis.
Maternal RBCs AA and total n-6 LCPUFAs were significantly negatively related to BMI (Table 3 ) and PI at 1 year pp (data not shown).
Importantly, neither the maternal RBCs DHA, EPA, AA, n-3 LCPUFAs, n-6 LCPUFAs nor the AA/DHA or the n-6/n-3 LCPUFAs ratio were consistently associated with individual SFT's (data not shown), the sum of the four skinfolds (Table 4) , or measures of abdominal ultrasonography (Supplementary file 1) at any time point studied during the first year of life.
Neonatal LCPUFAs in relation to infant growth parameters and fat mass We also examined the relationship between the neonatal RBCs fatty acid profile and infant outcomes up to 1 year of age. Neonatal EPA, n-3 LCPUFAs and DHA were significantly negatively related with parameters of neonatal body fat mass (g) at birth (Supplementary file 2). Neither neonatal RBCs DHA, EPA, AA, n-3 LCPUFAs, n-6 LCPUFAs nor the n-6/n-3 LCPUFAs or AA/DHA ratio were significantly correlated with the individual SFT's, the sum of the four skinfolds or parameters of fat mass at 1 year pp (data not shown).
DISCUSSION
The principle objective of this analysis was to study the relationship between the n-3 and n-6 LCPUFA profile and clinical outcomes, such as infant growth and particularly infant body composition. 
Both n-3 LCPUFA and n-6 LCPUFA are claimed as indispensable for infant growth and development, yet there is insufficient scientific evidence from existing randomized controlled trials to decide whether the individual LCPUFA profile of either mother or neonate is related to offspring growth. 22 Most evidence for possible growth-promoting effects of LCPUFAs to date is provided by cohort studies, where birth weight of term infants appeared to be positively associated with maternal n-3 LCPUFA concentrations, especially DHA, in early pregnancy. 23, 24 However, negative associations between DHA in umbilical cord plasma PLs and neonatal birth weight also have been reported. 25 The relationship of cord blood/maternal plasma PLs AA contents in pregnancy and at delivery with birth weight was mainly found to be negative [23] [24] [25] or rather neutral. 26 Evidence from randomized controlled trials is restricted to maternal n-3 LCPUFA intake and, although positive associations between maternal n-3 LCPUFA profile and weight dimensions at birth have also been reported, these are commonly interpreted as the consequence of prolonged gestation rather than a direct effect on fetal growth. Values marked with stars show significant differences between groups (Mann À Whitney-U-Test, *Po 0.05; **Po0.01, ***Po0.001). SFA: C4:0-C27:0. MUFA: sum of all cis-FA with one double bound. PUFA: sum of all cis-FA with two or more double bounds. n-6 LCPUFA: C20:2n-6; 20:3n-6; 20:4n-6; C22:2n-6; C22:4n-6; C22:5n-6. n-3 LCPUFA: C20:3n-3; C20:4n-3; 20:5n-3; C21:5n-3; C22:3n-3; 22:5n-3; 22:6n-3. 
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The results of the INFAT-study suggest that maternal RBCs DHA, EPA, total n-3 LCPUFAs, AA and total n-6 LCPUFAs in the last trimester serve as important fetal growth factors, as these maternal LCPUFAs were found to be significantly positively related to infant weight, length and lean body mass at birth. Of note, this relationship was still apparent after adjustment for cofactors such as pregnancy duration, parity and sex, known to be relevant determinants of fetal growth, 30 indicating a direct effect on these fatty acids on growth dimensions. For RBCs DHA, EPA and total n-3 LCPUFAs the observed association with weight and lean body mass at birth was no longer detectable at later stages of infant growth up to the first year of life, suggesting that these fatty acids indeed promote prenatal growth, rather than have an impact on postnatal growth. Our results are in line with a recent trial with follow-up over two decades, which was unable to detect an effect of fish oil in the 3rd trimester of pregnancy on adiposity in the 19-year-old offspring. 31 On the contrary, maternal RBCs AA and n-6 LCPUFAs were significantly negatively correlated with BMI and PI at 1 year of life within the present study. Interestingly, this relationship was still evident after correction for relevant confounders, known to influence perinatal growth 30 or fatty acid profile. 7, 9, 32, 33 This observation might indicate that maternal RBCs n-6 LCPUFAs not only serve as prenatal growth promotors, but also as determinants of postnatal overall growth within the first year of life. This surprising finding is hard to explain. However, the observed effects on infant growth, regardless of potential mechanisms, 34 are clinically relevant, as infant weight, length and BMI of the supplemented group was comparable to growth in the control group. 13 Of note, we found a significant negative relationship between umbilical cord blood RBCs concentrations of DHA, EPA and n-3 LCPUFAs with parameters of infant fat mass at birth and 6 weeks pp, but this association was not detectable at later stages up to age 1year. This result seems to be in line with the results of Helland et al. 35 observing no significant correlations between cord blood plasma PLs DHA and the ratio of n-6/n-3 fatty acids and children's BMI at 7 years of age.
The first randomized controlled trial to investigate the effect of n-3 LCPUFAs vs n-6 LCPUFAs intake during the first 9-18 months of infancy on adipose tissue growth, found no association between fish oil consumption relative to sunflower oil consumption and any of the anthropometric measures related to the size of the fat mass (z-Scores SFT) in the completing 133 infants, but a lower triceps-to-subscapular skinfold ratio at 18 months was reported in the infants from the fish oil group. 36 Recently, a large US cohort study reported that higher n-3 LCPUFA concentrations in the maternal diet and in umbilical cord blood plasma PLs are associated with a lower obesity rate in children at 3 year of age, measured by the sum of two SFT's (triceps þ subscapular), odds of obesity (BMI X 95th percentile compared with BMI o 85th Percentile) and infant leptin, a biomarker directly linked to fat mass. 37 Although these findings appear contradictory, one has to consider the difference in age of the children in these studies, 18 months, 3 and 7 years. To clarify this important issue, there is certainly a need for additional studies.
This observational study wanted to explore in detail the association between circulating maternal and fetal LCPUFA concentrations and body composition up to the first year of life assessed by SFT measurements and abdominal sonography. We acknowledge that the data presented are associations between biomarkers and anthropometric measures, which may not provide information about cause and effect relationships.
We found, that maternal RBCs DHA and n-3 LCPUFAs at 32nd week of gestation were significantly positively related with newborn length and lean body mass (g) at birth, even when corrected for gestational age, parity, sex and group. We interpret Fatty acids in relation to infant body composition D Much et al this result more as a growth-promoting, rather than an adipogenic effect of these maternal fatty acids. This interpretation is supported by the fact that neither the individual maternal LCPUFAs (DHA, EPA and AA), their sums (n-3 LCPUFAs, n-6 LCPUFAs) or their ratios (AA/DHA, n-6/n-3 LCPUFAs ratio) during late pregnancy were significantly associated with offspring body fat mass as assessed by longitudinal SFT measurements and abdominal ultrasonography from birth throughout the first year of life. Interestingly, we saw some negative associations between neonatal RBCs EPA, DHA and total n-3 LCPUFAs with single parameters of fat mass (for example, percentage body fat, subscapular SFT), but not with lean body mass at birth, indicating that circulating LCPUFAs in umbilical cord blood might have some role for adipose tissue growth in the newborns. However, if at all, this effect seems to be confined to the phase around birth, as neither neonatal RBCs DHA, EPA, AA, n-3 LCPUFAs, n-6 LCPUFAs nor the n-6/n-3 LCPUFAs or AA/DHA ratio were significantly correlated with the individual SFT's, the sum of the four skinfolds or parameters of fat mass at later stages up to 1 year pp.
These findings once more highlight the importance of adequate methods to assess body composition development in early life. Obviously, BMI data alone do not provide sufficient information on body composition and, therefore, should be interpreted with caution. Especially in early infancy, SFT measurements and sonographic assessment of subcutaneous fat tissues may provide a better assessment of body fat mass and, more indirectly, of LBM. BMI data do not distinguish between these two major components of body mass and may promote misinterpretation with regard to the relationship between fatty acids and body composition. Nevertheless, sonographic assessment of body composition might have limited precision in 1 year olds due to the relatively thin fat layers and frequent restlessness of infants. 17 Taken together, as already indicated by the analysis of the fatty acid intake data and adipose tissue development, 13 this detailed measurements of the fatty acids profile in maternal blood -as well as in umbilical cord blood -do not support the concept that maternal n-3 LCPUFAs exert an antiadipogenic action and, therefore, contradict previous findings in animal studies 5 and most available human data with and without such detailed measurements, 37, 38 except for a recent follow-up of a Danish trial. 31 However, to definitely clarify the role of the n-3 LCPUFA profile and the n-3/n-6 fatty acid balance on infant body composition more long-term studies with appropriate methods to assess adipose tissue development and body composition are necessary.
It is tempting to speculate that the genetic heterogeneity in fatty acid metabolism (for example, polymorphisms in FADS1/2) may be one of the reasons (besides differences in study design and/or quality) for the apparent inconsistent results of several studies that investigated the effects of perinatal n-3 LCPUFAs supplementation on clinical outcomes. This new important confounder has to be taken into consideration in future analyses to clarify possible gene-nutrient interactions and to enhance study sensitivity and precision.
